论文部分内容阅读
目的分析研究依达拉奉治疗急性缺血性脑梗死的临床效果和安全性。方法选择2010年1月至2011年1月期间我院收治的急性脑梗死患者78例,随机分为治疗组和对照组各39例,对照组采用常规方法治疗,治疗组在常规治疗的基础上加用依达拉奉,评定治疗前后两组的神经功能缺损和临床疗效。结果治疗后两组的神经功能缺损评分均明显改善,且治疗组评分改善优于对照组(P<0.05);治疗组总有效率为89.74%,对照组总有效率为74.36%,治疗组总有效率高于对照组,两组比较差异有统计学意义(P<0.05)。结论依达拉奉可有效的改善急性脑梗死患者的神经功能缺失,治疗急性缺血性脑梗死的疗效肯定。
Objective To analyze the clinical effect and safety of edaravone in the treatment of acute ischemic cerebral infarction. Methods 78 patients with acute cerebral infarction admitted to our hospital from January 2010 to January 2011 were randomly divided into treatment group (39 cases) and control group (39 cases). The control group was treated by conventional method. On the basis of routine treatment Add edaravone, before and after treatment to assess the two groups of neurological deficit and clinical efficacy. Results After treatment, the scores of neurological deficit in both groups were significantly improved, and the treatment group score improved better than the control group (P <0.05). The total effective rate was 89.74% in the treatment group and 74.36% in the control group. The total effective rate Efficacy than the control group, the difference between the two groups was statistically significant (P <0.05). Conclusion Edaravone can effectively improve the neurological deficits in patients with acute cerebral infarction, the treatment of acute ischemic stroke is sure.